Tammi L. Gaskins, Chief Commercial Officer of Ironwood Pharmaceuticals Inc, filed a Form 4 on November 18, 2026, disclosing the sale of 5,919 shares of Class A Common Stock on November 16, 2026, to cover tax withholding obligations arising from the vesting of restricted stock units.
Key Highlights
- Reporting person: Tammi L. Gaskins, Chief Commercial Officer of Ironwood Pharmaceuticals Inc (NASDAQ:IRWD)
- Shares disposed: 5,919 shares of Class A Common Stock sold on November 16, 2026
- Sale price: $4.81 per share
- Purpose: According to the filing, the sale was required to cover tax withholding obligations connected to the vesting of restricted stock units and occurred automatically via a sell-to-cover transaction
- Remaining holdings: 344,431 shares of Class A Common Stock beneficially owned directly following the transaction
- Non-discretionary: The filing states the sale "does not represent a discretionary trade by the reporting person"
Tax-Driven RSU Vest Sale by Ironwood Pharmaceuticals Chief Commercial Officer
According to the Form 4 filed with the U.S. Securities and Exchange Commission, Tammi L. Gaskins, serving as Chief Commercial Officer at Ironwood Pharmaceuticals Inc, disposed of 5,919 shares of Class A Common Stock on November 16, 2026, at a price of $4.81 per share. The filing identifies the transaction code as "S," indicating a sale in the open market.
The filing's footnote explains that the reported sale "represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units." The filing further states that "the sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person." Following the transaction, Gaskins directly holds 344,431 shares of Class A Common Stock, as reported in Table I of the filing.
No derivative securities transactions were reported in Table II of the filing. The Form 4 was signed by Amir Vitale as Attorney-in-Fact on November 18, 2026, and was filed on behalf of Gaskins as an individual reporting person. No amendment date was indicated, suggesting this is an original filing.
What Was Disclosed
Ironwood Pharmaceuticals' Chief Commercial Officer Tammi L. Gaskins disclosed a sale of 5,919 Class A Common Stock shares at $4.81 per share on November 16, 2026, automatically executed to satisfy tax withholding on vesting restricted stock units, leaving her with 344,431 shares directly held.



Please wait processing your request...